Open access
114
Views
0
CrossRef citations to date
0
Altmetric
Research
Maximizing the benefits of using biosimilars in Egypt
Ahmad Nader Fasseeh1 Syreon Middle EastAlexandriaEgypt;2 Faculty of Pharmacy, Alexandria UniversityAlexandriaEgyptCorrespondence[email protected]
https://orcid.org/0000-0001-9878-7734
Baher Elezbawy1 Syreon Middle EastAlexandriaEgypt
, Kareem Ahmed El-Fass1 Syreon Middle EastAlexandriaEgypt
, Mary GamaI3 Egyptian Authority for Unified Procurement, Medical Supply and Technology ManagementCairoEgypt
, Ahmed Seyam4 Universal Health Insurance AuthorityCairoEgypt
, Noha Hayek5 Theodor Bilharz Research InstituteGizaEgypt
, Nagwan Abdel Rahman6 Health Insurance OrganizationCairoEgypt
, Sohir Abdelhamid7 Egyptian Parliament Health SectorCairoEgypt
, Nader Fasseeh8 Faculty of Medicine, Alexandria UniversityAlexandriaEgypt
, Amr Shafik Saad9 Faculty of Medicine, Ain Shams UniversityCairoEgypt
, Ahmed Elagamy3 Egyptian Authority for Unified Procurement, Medical Supply and Technology ManagementCairoEgypt
, Akram Mahmoud6 Health Insurance OrganizationCairoEgypt
, Amal Samir Sedrak4 Universal Health Insurance AuthorityCairoEgypt;10 Faculty of MedicineCairo UniversityCairoEgypt
, Khaled Elshazly11 Presidential Program for Women’s HealthCairoEgypt
, Mariam Eldebeiky3 Egyptian Authority for Unified Procurement, Medical Supply and Technology ManagementCairoEgypt
, Monica Talaat12 Egyptian Drug AuthorityCairoEgypt
, Noura Maher Mohamed4 Universal Health Insurance AuthorityCairoEgypt
, Rania Ahmed Abdelaziz4 Universal Health Insurance AuthorityCairoEgypt
, Remonda Refaat3 Egyptian Authority for Unified Procurement, Medical Supply and Technology ManagementCairoEgypt
, Shaimaa Akeel3 Egyptian Authority for Unified Procurement, Medical Supply and Technology ManagementCairoEgypt
, Sherif Abaza1 Syreon Middle EastAlexandriaEgypt
& Zoltán Kaló13 Semmelweis UniversityBudapestHungary;14 Syreon Research InstituteBudapestHungary
show all
Article: 79
|
Received 04 Feb 2023, Accepted 06 Jun 2023, Published online: 11 Mar 2024
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.